BofA analyst Jason Zemansky raised the firm's price target on Rocket Pharmaceuticals to $9 from $8 and keeps a Buy rating on the shares. Following Kresladi's approval, the firm is adjusting sales estimates to reflect updated timelines and its model for Q4 updates, telling investors it views the stock's negative reaction after approval as "surprising" given that Rocket's call to discuss Kresladi's approval didn't provide many new updates. However, the firm acknowledges details around timelines and the lack of pricing commentary "may have disappointed," the analyst added.
